BridgeBio Pharma, Inc. – NASDAQ:BBIO
Founder-led company
BridgeBio Pharma stock price today
$49.75
+21.76
+77.74%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
BridgeBio Pharma stock price monthly change
+3.21%
month
BridgeBio Pharma stock price quarterly change
+3.21%
quarter
BridgeBio Pharma stock price yearly change
-36.23%
year
BridgeBio Pharma key metrics
Market Cap | 5.12B |
Enterprise value | 3.64B |
P/E | -4.88 |
EV/Sales | 46.88 |
EV/EBITDA | -9.24 |
Price/Sales | 29.54 |
Price/Book | -1.82 |
PEG ratio | -0.29 |
EPS | -3.22 |
Revenue | 218.59M |
EBITDA | -456.52M |
Income | -538.26M |
Revenue Q/Q | 11461.88% |
Revenue Y/Y | 181.04% |
Profit margin | -619.7% |
Oper. margin | -603.28% |
Gross margin | 95.58% |
EBIT margin | -603.28% |
EBITDA margin | -208.84% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBridgeBio Pharma stock price history
BridgeBio Pharma stock forecast
BridgeBio Pharma financial statements
Average Price Target
$47.5
Potential downside: -4.52%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.64M | -157.89M | -9622.12% |
|---|---|---|---|
| Sep 2023 | 4.09M | -176.99M | -4326.55% |
| Dec 2023 | 1.74M | -168.14M | -9635.99% |
| Mar 2024 | 211.12M | -35.21M | -16.68% |
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 0.03% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 503661000 | 1.85B | 367.97% |
|---|---|---|---|
| Sep 2023 | 655008000 | 1.84B | 282.25% |
| Dec 2023 | 546380000 | 1.88B | 345.71% |
| Mar 2024 | 849333000 | 1.88B | 222.08% |
| Jun 2023 | -113.35M | 4.11M | -1.23M |
|---|---|---|---|
| Sep 2023 | -145.22M | 37.68M | 307.04M |
| Dec 2023 | -124.81M | -66K | -4.52M |
| Mar 2024 | -219.53M | 22.75M | 279.54M |
BridgeBio Pharma alternative data
| Aug 2023 | 392 |
|---|---|
| Sep 2023 | 392 |
| Oct 2023 | 392 |
| Nov 2023 | 392 |
| Dec 2023 | 392 |
| Jan 2024 | 392 |
| Feb 2024 | 392 |
| Mar 2024 | 550 |
| Apr 2024 | 550 |
| May 2024 | 550 |
| Jun 2024 | 550 |
| Jul 2024 | 550 |
BridgeBio Pharma other data
90.82%
-4.77%
of BBIO is owned by hedge funds
157
+4
133.22M
-6.22M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 104915 |
| Jan 2024 | 0 | 2915 |
| Feb 2024 | 0 | 2915 |
| Mar 2024 | 0 | 2500 |
| Jun 2024 | 0 | 2500 |
| Aug 2024 | 0 | 31544 |
| Sep 2024 | 0 | 5800000 |
| Nov 2024 | 0 | 31545 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | KUMAR NEIL director, officer.. | Common Stock | 25,514 | $22.39 | $571,156 | ||
Sale | KUMAR NEIL director, officer.. | Common Stock | 1,875 | $22.76 | $42,681 | ||
Sale | STEPHENSON BRIAN C officer: Secretary, Treasurer &.. | Common Stock | 4,156 | $22.41 | $93,136 | ||
Option | KUMAR NEIL director, officer.. | Common Stock | 55,537 | N/A | N/A | ||
Option | KUMAR NEIL director, officer.. | Restricted Stock Units | 33,544 | N/A | N/A | ||
Option | KUMAR NEIL director, officer.. | Restricted Stock Units | 19,599 | N/A | N/A | ||
Option | KUMAR NEIL director, officer.. | Restricted Stock Units | 2,394 | N/A | N/A | ||
Option | STEPHENSON BRIAN C officer: Secretary, Treasurer &.. | Restricted Stock Units | 17,369 | N/A | N/A | ||
Option | STEPHENSON BRIAN C officer: Secretary, Treasurer &.. | Common Stock | 25,799 | N/A | N/A | ||
Option | STEPHENSON BRIAN C officer: Secretary, Treasurer &.. | Restricted Stock Units | 6,705 | N/A | N/A |
| Insider | Compensation |
|---|---|
| Dr. Neil Kumar Ph.D. (1979) Co-Founder, Chief Executive Officer & Director | $1,390,000 |
Dr. Brian C. Stephenson C.F.A., Ph.D. (1981) Chief Financial Officer, Sec. & Principal Accounting Officer | $1,270,000 |
| Dr. Michael Thomas Henderson M.D. (1990) Chief Bus. Officer | $826,840 |
| Dr. Charles J. Homcy M.D. (1948) Chairman of Pharmaceuticals & Lead Director | $655,810 |
| Dr. Richard H. Scheller Ph.D. (1953) Chairman of R&D and Director | $650,000 |
Dr. Cameron Turtle DPHIL, Ph.D. (1990) Chief Strategy Officer | $621,400 |
Pfizer Looks Like A Great Play At Current Valuations
BridgeBio: Early Signs Point To Blockbuster Revenues
BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster
Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
An Update On Ascendis Pharma's Path To Profitability
BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner
-
What's the price of BridgeBio Pharma stock today?
One share of BridgeBio Pharma stock can currently be purchased for approximately $49.75.
-
When is BridgeBio Pharma's next earnings date?
Unfortunately, BridgeBio Pharma's (BBIO) next earnings date is currently unknown.
-
Does BridgeBio Pharma pay dividends?
No, BridgeBio Pharma does not pay dividends.
-
How much money does BridgeBio Pharma make?
BridgeBio Pharma has a market capitalization of 5.12B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 88.02% to 9.3M US dollars.
-
What is BridgeBio Pharma's stock symbol?
BridgeBio Pharma, Inc. is traded on the NASDAQ under the ticker symbol "BBIO".
-
What is BridgeBio Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BridgeBio Pharma?
Shares of BridgeBio Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BridgeBio Pharma's key executives?
BridgeBio Pharma's management team includes the following people:
- Dr. Neil Kumar Ph.D. Co-Founder, Chief Executive Officer & Director(age: 46, pay: $1,390,000)
- Dr. Brian C. Stephenson C.F.A., Ph.D. Chief Financial Officer, Sec. & Principal Accounting Officer(age: 44, pay: $1,270,000)
- Dr. Michael Thomas Henderson M.D. Chief Bus. Officer(age: 35, pay: $826,840)
- Dr. Charles J. Homcy M.D. Chairman of Pharmaceuticals & Lead Director(age: 77, pay: $655,810)
- Dr. Richard H. Scheller Ph.D. Chairman of R&D and Director(age: 72, pay: $650,000)
- Dr. Cameron Turtle DPHIL, Ph.D. Chief Strategy Officer(age: 35, pay: $621,400)
-
Is BridgeBio Pharma founder-led company?
Yes, BridgeBio Pharma is a company led by its founder Dr. Neil Kumar Ph.D..
-
How many employees does BridgeBio Pharma have?
As Jul 2024, BridgeBio Pharma employs 550 workers.
-
When BridgeBio Pharma went public?
BridgeBio Pharma, Inc. is publicly traded company for more then 6 years since IPO on 27 Jun 2019.
-
What is BridgeBio Pharma's official website?
The official website for BridgeBio Pharma is bridgebio.com.
-
Where are BridgeBio Pharma's headquarters?
BridgeBio Pharma is headquartered at 421 Kipling Street, Palo Alto, CA.
-
How can i contact BridgeBio Pharma?
BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto, CA and company can be reached via phone at +65 03919740.
-
What is BridgeBio Pharma stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for BridgeBio Pharma in the last 12 months, the avarage price target is $47.5. The average price target represents a -4.52% change from the last price of $49.75.
BridgeBio Pharma company profile:
BridgeBio Pharma, Inc.
bridgebio.comExchange:
NASDAQ
Full time employees:
550
Industry:
Biotechnology
Sector:
Healthcare
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
421 Kipling Street
Palo Alto, CA 94301
Palo Alto, CA 94301
CIK: 0001743881
ISIN: US10806X1028
CUSIP: 10806X102
